Quad Screen: Nursing Guide
The quadruple (quad) screen measures four maternal serum markers in the second trimester to estimate risk for trisomy 21, trisomy 18, and open neural tube defects — it is screening, not a fetal diagnosis. Nurses verify gestational dating, collect serum correctly, support patients after screen-positive risk reports, coordinate anatomy ultrasound and genetics counseling, and avoid charting confirmed aneuploidy or neural tube defects from screening alone.
Contents
Quick Facts
Key Takeaway
The quad screen combines four serum markers into risk estimates — a screen-positive result requires obstetric or genetics follow-up and often detailed ultrasound, and a screen-negative result does not guarantee absence of.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Gold-top serum gel (preferred) or red-top
Serum separator or plain serum per laboratory maternal screening protocol
Maternal serum (venous blood)
Typically ≥0.5–0.6 mL serum — follow institutional minimum volume
Second-trimester maternal quad window per laboratory protocol (commonly approximately 15 0/7 to 22 6/7 weeks gestation — optimal timing often 16–18 weeks for neural tube defect screening per obstetric guidance)
No special preparation is usually required AFP guidance
Refrigerated serum commonly acceptable per laboratory; avoid hemolysis. Follow local transport and stability policy.
Often 3–7 days for send-out maternal screening — stat timing not specified in reviewed references
Maternal serum screening / prenatal chemistry send-out
What is Quad Screen?
Quad Screen is a second-trimester prenatal screening blood test that measures four substances in maternal serum: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE3), and dimeric inhibin A. Laboratories combine these marker levels with maternal factors such as age, weight, diabetes status, and fetal number to estimate risk for trisomy 21 (Down syndrome), trisomy 18, and open neural tube defects. Results are screening estimates, not fetal diagnoses.
Overview
Antepartum nurses support quad screening by confirming the order is a maternal quadruple panel (not adult tumor marker alpha-fetoprotein), verifying gestational age in the laboratory window, and teaching that abnormal results lead to ultrasound and counseling — not immediate diagnosis. AFP is measured during pregnancy as part of the larger quadruple screen blood test set.
obstetric guidelines guidance describes quad screening from about 15 to 22 weeks gestation for patients who need second-trimester serum screening. Non-invasive prenatal testing (NIPT) may be offered in other pathways but does not replace second-trimester AFP-based open neural tube defect screening where those are used. Neural tube defect screening pathways often share the AFP component interpreted with the full quad panel.
Before venipuncture, confirm gestational dating, fetal number when known, and requisition fields required for risk calculation. After results, record exact screen classification or risk wording, notify obstetric teams for screen-positive reports, schedule or confirm anatomy ultrasound, and teach screening limits — evaluate outcomes when imaging and counseling are completed.
Screen-Positive Quad Results and Diagnostic Language Safety
The quadruple (quad) screen estimates fetal risk from four maternal serum markers — it does not diagnose Down syndrome, trisomy 18, or open neural tube defects at the bedside. Nurses prevent harm by verifying gestational dating before collection, using screening language after high-risk reports, and ensuring obstetric or genetics follow-up before patients make irreversible decisions.
- Charting or disclosing confirmed trisomy 21 or open neural tube defect from a screen-positive quad result alone
- Drawing quad markers with uncertain gestational age or outside the laboratory screening window
- Screen-positive aneuploidy or elevated AFP MoM without documented obstetric notification or follow-up imaging plan
- Reassuring a patient that a screen-negative quad guarantees a chromosomally typical fetus or absence of structural anomalies
Document: gestational age source, panel components ordered, risk classification or MoM values as reported, patient teaching on screening limits, obstetric or genetics notifications, and scheduled ultrasound or diagnostic testing discussions.
What the Quad Screen Can and Cannot Tell You
This test can help identify:
- Adjusted population risk estimates for trisomy 21, trisomy 18, and open neural tube defects when drawn in the appropriate gestational window
- Need for detailed fetal anatomy ultrasound, genetics counseling, and possible diagnostic testing after screen-positive results
- Discordant marker patterns (for example isolated AFP MoM elevation) that may prompt targeted imaging or specialist review
- Whether repeat or alternate screening may be needed after incorrect dating or incomplete panel reporting
This test cannot:
- Diagnose Down syndrome, trisomy 18, spina bifida, or anencephaly by itself
- Replace diagnostic chromosome analysis when patients will act on a high-risk screen
- Detect all chromosomal abnormalities, microdeletions, or structural anomalies outside the screened conditions
- Guarantee a healthy fetus after a screen-negative result — routine ultrasound and obstetric care continue
Gestational Dating and Quad Panel Specimen Checks
Verify
Clarify before proceeding when:
- Gestational age conflicts between last menstrual period and ultrasound or falls outside the laboratory window
- Order lists tumor marker AFP on a pregnant patient without obstetric quad panel clarification
- Specimen label, tube type, or patient identity does not match
- Patient expects the blood test to definitively show chromosome or spine problems
- Screen-positive quad result is known but no anatomy ultrasound or obstetric follow-up is documented
- Twin pregnancy or fetal demise since dating — marker interpretation may be misleading
- Patient plans major pregnancy decisions from an online risk ratio without counseling
Four Markers, MoM Values, and Combined Risk Reporting
The quad screen measures four maternal serum analytes — alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE3), and dimeric inhibin A — with maternal factors such as age, weight, diabetes status, and plurality to calculate risk estimates. Laboratories often report individual multiples of the median (MoM) plus combined risks for trisomy 21, trisomy 18, and open neural tube defects.
| Marker / report element | Clinical meaning for nurses | Typical nursing action |
|---|---|---|
| AFP MoM (elevated) | May increase estimated open NTD risk and other AFP-related conditions per laboratory interpretation | Notify obstetric team; coordinate targeted ultrasound — do not diagnose spina bifida at bedside |
| Low hCG or uE3 MoM with other markers | May contribute to screen-positive aneuploidy risk on the combined algorithm | Route full panel report to obstetric reviewer; avoid interpreting one marker alone |
| Screen-positive trisomy 21 risk | Increased probability — not diagnostic until confirmatory testing when results change management | Arrange genetics or obstetric counseling; document screening language only |
| Screen-negative combined risk | Lower estimated risk on this assay for screened conditions | Continue routine care; teach screening limits and planned anatomy imaging |
| Wrong gestational age on requisition | Can falsely raise or lower MoM and combined risks | Clarify dating before alarming language; repeat only per prescriber and laboratory guidance |
On a small screen, swipe or scroll sideways to see the full table.
Reference ranges, MoM cutoffs, risk ratios, and critical values may vary by laboratory, institution, analyzer, maternal weight, diabetes status, and clinical context. Always interpret results using the reporting laboratory’s reference materials and local escalation policy.
Integrating Quad Risk With Ultrasound and Maternal Age
Pair quad risk labels with reliable gestational dating, maternal age, fetal number, and detailed fetal anatomy imaging — not patient anxiety alone. A screen-positive trisomy 21 report still needs counseling about positive predictive value; a screen-negative quad with abnormal ultrasound still requires obstetric follow-up.
| Clinical pattern | May suggest | Nursing focus |
|---|---|---|
| Screen-positive trisomy 21 with normal early ultrasound | Increased screening risk pending counseling and possible diagnostic testing | Screening language only; ensure genetics or obstetric visit; evaluate outcomes after disclosure |
| Elevated AFP MoM with screen-negative aneuploidy risk | Open NTD or alternate AFP elevation pathway | Coordinate targeted ultrasound; avoid definitive fetal anomaly statements |
| Screen-negative quad with suspicious anatomy findings | Discordant results — ultrasound may detect problems serum screening misses | Notify MFM or obstetrics; do not dismiss imaging findings because quad was negative |
| Screen-positive trisomy 18 risk | High clinical concern per obstetric protocol | Urgent specialist follow-up per institutional pathway; sensitive communication planning |
On a small screen, swipe or scroll sideways to see the full table.
Quad Screen Timing Traps and Patient Anxiety
| Bedside point | Nursing note |
|---|---|
| Screen ≠ diagnosis | Say “screen-positive” or “increased risk” — not “your baby has Down syndrome” |
| Dating drives MoM | Confirm gestational age on every quad draw; wrong dates are a common false-positive driver |
| Four markers, one report | Route the full laboratory obstetric interpretation — not isolated AFP or hCG values alone |
| Negative is not absolute | Teach that screening lowers but does not eliminate risk for screened conditions |
| NIPT is different | Cell-free DNA and quad screening answer overlapping but not identical questions — follow obstetric plan |
| Follow-through | Evaluate outcomes by confirming anatomy ultrasound and counseling occur after screen-positive results |
On a small screen, swipe or scroll sideways to see the full table.
Why Quad Screen is Ordered
The quad screen is offered in prenatal care to estimate risk for common fetal chromosome problems and open neural tube defects when patients undergo second-trimester serum screening.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Second-trimester aneuploidy risk assessment (trisomy 21 and trisomy 18) | Is estimated fetal chromosome abnormality risk increased on this panel? | Combined marker algorithms report screen-positive or screen-negative risk estimates per laboratory — nurses route results to obstetric reviewers without diagnosing at bedside. |
| Open neural tube defect risk via maternal serum AFP MoM | Does elevated AFP MoM on the quad panel increase open NTD risk on this assay? | obstetric guidelines notes quad screening provides open fetal defect risk information alongside aneuploidy assessment — elevated AFP MoM prompts targeted ultrasound per obstetric protocol. |
| Patients without first-trimester combined screening who elect second-trimester serum screening | Should quad screening be offered per institutional obstetric pathway? | standard clinical references and obstetric guidelines describe quad screening as a second-trimester option when first-trimester pathways were not completed or when serum screening remains part of the plan. |
| Follow-up after uncertain dating or discordant prior screening | Should quad markers be repeated or reinterpreted after corrected gestational age? | Incorrect dating decreases screening accuracy per obstetric guidelines — prescriber and laboratory guidance determine repeat testing. |
Contraindications and Precautions
There is no absolute contraindication to maternal venipuncture for quad screening when ordered. Do not collect when identity or labels are uncertain, or when the order type (maternal quad panel versus tumor marker AFP) is unresolved.
- Telling a patient a screen-positive quad result confirms Down syndrome or spina bifida before ultrasound or diagnostic testing
- Drawing quad markers without verified gestational age in the laboratory screening window
- Screen-positive risk report without documented obstetric notification or follow-up imaging plan
- Multiple gestation, fetal demise, and maternal weight can affect MoM — document context on the chart
- Screen-negative results do not exclude all chromosome or structural anomalies
- Risk cutoffs, MoM values, and panel wording vary by laboratory — use the reporting laboratory interpretation
- Screen-positive quad without scheduled or completed obstetric review and ultrasound plan
- Markedly discordant MoM with uncertain gestational age or twin pregnancy not documented
- Patient distress or self-harm risk after screen-positive result — activate behavioral health pathway per policy
Patient Preparation
Preparation focuses on dating verification, order clarification, emotional support, and correct serum collection — fasting is usually not required.
Pre-test checksDocument insulin-treated diabetes and antiepileptic medicines when recorded — maternal screening MoM calculations may adjust for diabetes status per laboratory protocol. Do not withhold prescribed medicines unless prescriber orders — review for interpretation context only.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Quad Screen. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Quad screening reports individual MoM values for AFP, hCG, uE3, and inhibin A plus combined risk estimates for trisomy 21, trisomy 18, and open neural tube defects per laboratory format. Nurses record exact wording, notify obstetrics or genetics per protocol, and avoid converting risk ratios into definitive fetal diagnoses.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Negative / not detected | Screen-negative or low-risk classification per laboratory obstetric report | Lower estimated risk for screened conditions on this assay in current context | Continue routine prenatal care and planned anatomy imaging; reinforce screening limits |
| Equivocal / borderline | Borderline MoM or risk near institutional cutoff | May require laboratory or obstetric review depending on local policy | Confirm dating; communicate result per protocol without diagnosing fetal anomaly |
| Positive / elevated | Screen-positive aneuploidy risk or elevated AFP MoM per report | Increased estimated risk — not diagnostic until confirmatory testing when results change management | Notify obstetric team; coordinate ultrasound and genetics counseling; use screening language only |
| Not applicable / below detection limit | Markedly low uE3 or other isolated marker pattern on panel | May trigger additional review on some assays — follow full laboratory obstetric interpretation | Route complete panel report to obstetric reviewer; do not interpret one marker alone |
Screen-Positive Quad Results and Delayed Obstetric Follow-Up
Universal laboratory critical MoM thresholds for quad screening are Turnaround and screening rules vary by institution; follow local institutional policy. Clinical urgency often reflects screen-positive classification with missing ultrasound, unresolved dating, or acute patient safety concerns.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Screen-positive aneuploidy risk without obstetric contact | High-risk trisomy 21 or trisomy 18 screen per laboratory report with no documented notification | Notify obstetric or genetics team per facility policy; track counseling and imaging appointments |
| Elevated AFP MoM without imaging plan | Screen-positive open NTD risk or markedly elevated AFP MoM on panel | Coordinate targeted ultrasound and obstetric review — do not diagnose spina bifida at bedside |
| Acute behavioral health risk after screen-positive counseling | Patient expresses self-harm thoughts or severe distress after result disclosure | Activate behavioral health and obstetric support pathways per institutional protocol |
Escalate according to facility policy when screen-positive quad results lack timely obstetric follow-up, dating remains uncertain, the patient plans major decisions without counseling, or acute maternal-fetal symptoms develop.
Factors Affecting Results
Quad risk interpretation depends on accurate gestational age, assay method, and maternal factors used in laboratory adjustment algorithms.
- Incorrect gestational age — common cause of false-positive MoM and risk estimates
- Multiple gestation — marker levels differ from singleton reference expectations
- Fetal abdominal wall defects — may elevate AFP without open neural tube defect
- Screen-negative quad with fetal anomaly on ultrasound — screening does not detect all problems
- Closed neural tube defects may not significantly raise maternal serum AFP
- Assuming screen-negative risk excludes all trisomy 18 or 21 cases
- Wrong gestational age or outdated dating source
- Maternal weight, race/ethnicity, and diabetes adjustments per laboratory
- Hemolyzed or mislabeled serum specimen
Quad screening estimates risk for selected conditions and cannot diagnose chromosome abnormalities or neural tube defects. Confirmatory testing such as karyotype after invasive sampling may be offered when results will change management. Screening does not detect all structural anomalies, microdeletions, or single-gene disorders.
Nursing Responsibilities
Nursing care centers on dating verification, safe specimen handling, accurate result communication, emotional support, and tracking obstetric follow-through after screen-positive reports.
Before the TestDocumentation
Documentation should show correct screening context, risk classification or MoM values, communication, and follow-up without overinterpreting screening as diagnosis.
“Quad screen serum drawn 1015 at 17+3 weeks (dating: ultrasound 12+5 w). Gold-top serum; labels verified at bedside. Result: screen-positive trisomy 21 risk (1:85 per laboratory); AFP MoM 1.1. Patient anxious; teaching provided that this is a screening result requiring specialist follow-up — not a confirmed diagnosis. Obstetric NP notified 1530; detailed anatomy ultrasound scheduled 24 Jun. Evaluate outcomes at imaging and counseling visits.”
- Gestational age, dating source, fetal number, and maternal factors on requisition
- Order type (quadruple panel) and specimen collection details
- MoM values and screen classification with laboratory reference wording
- Obstetric or genetics notification, read-back, and follow-up imaging plan
- Patient teaching on screening versus diagnostic limits
- Evaluate outcomes when ultrasound and counseling are completed
Patient and Family Education
Use plain language that the quad screen estimates risk from four blood markers and that more tests may be needed after an abnormal result.
Quad Screen NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Quad Screen safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Quadruple (quad) maternal serum screening panel
- Indication: Second-trimester aneuploidy and open NTD risk assessment at 17 weeks gestation
- Timing: Serum collected today; dating ultrasound confirms 17+2 weeks
- Related orders: Detailed fetal anatomy ultrasound scheduled in 3 days; routine prenatal labs on file
- Result: Screen-positive trisomy 21 risk (1:85 per laboratory); AFP MoM 1.1; other markers within laboratory expected range
- Trend / prior value: No prior quad screen; first-trimester combined screening not performed in this pregnancy
- Pending tests: Anatomy ultrasound not yet performed; genetics counseling referral not documented
- Vital signs: Temp 36.8°C, HR 80/min, BP 116/70 mmHg, RR 16/min, SpO₂ 99% room air
- Symptoms: No bleeding or abdominal pain; reports anxiety after previewing portal risk result
- Focused assessment: Singleton pregnancy on prior ultrasound; fundal height consistent with dates; patient tearful but coherent
- Preparation notes: Gestational age verified with clinic ultrasound record; pre-test education documented
- Collection events: Gold-top serum collected; labels correct; no hemolysis noted
- Teaching gaps / safety concerns: Patient states online article confirmed Down syndrome because risk is 1:85; no obstetric call documented yet
Answer key & rationale
Frequently Asked Questions
FAQ
What is the quad screen?
The quadruple (quad) screen measures four substances in maternal blood — AFP, hCG, unconjugated estriol, and inhibin A — to estimate risk for trisomy 21, trisomy 18, and open neural tube defects. It is a screening test, not a diagnostic chromosome or spine study.
When is the quad screen performed?
obstetric guidelines describes quad screening from approximately 15 0/7 to 22 6/7 weeks gestation, with many laboratories recommending collection around 16–18 weeks for neural tube defect screening. Confirm gestational age and local laboratory requirements on the order.
Does the patient need to fast before quad screening?
Usually no. no special preparation for AFP blood testing unless additional instructions appear on the order or local policy.
What does a screen-positive quad result mean?
A screen-positive result means the estimated risk for a screened condition exceeds the laboratory cutoff — it does not confirm the fetus has that condition. Obstetric teams interpret the report with dating, ultrasound, and sometimes diagnostic testing.
Can a screen-negative quad exclude all birth defects?
No. A screen-negative result lowers estimated risk for the screened conditions but does not rule out all chromosome problems, genetic disorders, or structural anomalies. Routine ultrasound and obstetric care continue.
How is the quad screen different from NIPT?
NIPT primarily screens selected chromosome problems using cell-free DNA. Quad screening uses four serum markers and includes open neural tube defect risk via AFP — pathways may differ per obstetric plan and neither replaces detailed fetal anatomy imaging.
What nursing action follows a screen-positive quad result?
Notify the obstetric or genetics team per protocol, support accurate patient teaching, coordinate targeted or detailed ultrasound and counseling, document communication, and evaluate outcomes when follow-up is complete.
References
References
-
U.S. National Library of Medicine. Alpha fetoprotein. MedlinePlus Medical Encyclopedia.https://medlineplus.gov/ency/article/003573.htm
-
American College of Obstetricians and Gynecologists. Screening for Fetal Chromosomal Abnormalities. ACOG Practice Bulletin No. 226.https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/10/screening-for-fetal-chromosomal-abnormalities
-
ARUP Laboratories. Maternal Serum Screen, Alpha Fetoprotein, hCG, Estriol, and Inhibin A (Quad). Test Directory.https://ltd.aruplab.com/Tests/Pub/3000143
-
Centers for Disease Control and Prevention. Neural Tube Defects. CDC.https://www.cdc.gov/ncbddd/birthdefects/neuraltube-defects.html
-
Adigun OO, Yarrarapu SNS, Zubair M, Khetarpal S. Alpha-Fetoprotein Analysis. StatPearls. NIH Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK539816/
-
National Health Service. Screening for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome. NHS UK.https://www.nhs.uk/pregnancy/your-pregnancy-care/screening-for-downs-edwards-pataus-syndrome/
-
Gardner RL, et al. Prenatal Genetic Screening. StatPearls. NIH Bookshelf; updated 2024.https://www.ncbi.nlm.nih.gov/books/NBK557702/
-
U.S. Preventive Services Task Force. Folic Acid Supplementation to Prevent Neural Tube Defects. JAMA, 2023.https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Quad Screen.
Policies: Medical Review Process · Editorial Policy · Correction Policy